LCG
TGTX icon

Lisanti Capital Growth’s TG Therapeutics TGTX Stock Holding History

Lisanti Capital Growth’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-193,460
Closed -$4.81M – 171
2023
Q2 		$4.81M Buy
+193,460
New +$5M 0.67% 66
2021
Q3 		– Sell
-111,955
Closed -$4.34M – 165
2021
Q2 		$4.34M Buy
+111,955
New +$4.4M 0.54% 78
2020
Q3 		– Sell
-187,795
Closed -$3.66M – 145
2020
Q2 		$3.66M Buy
187,795
+95,645
+104% +$1.54M 0.75% 69
2020
Q1 		$907K Buy
+92,150
New +$1.16M 0.3% 91

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Lisanti Capital Growth's TGTX Position: Q3 2023 in Review

Lisanti Capital Growth sold out of TG Therapeutics (TGTX) in Q3 2023, closing a stake of 193,460 shares — an estimated $4.81M sold.

Lisanti Capital Growth first reported a position in TGTX in Q1 2020 and held it in 4 quarters. The position peaked at $4.81M in Q2 2023. 236 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

  • Lisanti Capital Growth reported no remaining TG Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Lisanti Capital Growth sold 193,460 TG Therapeutics shares in Q3 2023, an estimated $4.81M.
  • Lisanti Capital Growth first reported a position in TG Therapeutics in Q1 2020 and held it in 4 quarters.
  • Lisanti Capital Growth's TG Therapeutics position peaked at $4.81M in Q2 2023.
  • 236 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on Lisanti Capital Growth's 13F filing for Q3 2023, filed 3 Nov 2023.